{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:38:02Z","timestamp":1772761082843,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s12325-018-0813-y","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T09:58:03Z","timestamp":1539683883000},"page":"1920-1934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain"],"prefix":"10.1007","volume":"35","author":[{"given":"Miguel","family":"Salavert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Arag\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Maratia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Aceituno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,16]]},"reference":[{"issue":"6","key":"813_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/1469-0691.12064","volume":"18","author":"E Bouza","year":"2012","unstructured":"Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect. 2012;18(6):5\u201312.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"813_CR2","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S1473-3099(14)70991-0","volume":"14","author":"KA Davies","year":"2014","unstructured":"Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F, Barna Z, et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis. 2014;14(12):1208\u201319.","journal-title":"Lancet Infect Dis."},{"issue":"8","key":"813_CR3","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s10096-015-2380-3","volume":"34","author":"L Alcal\u00e1","year":"2015","unstructured":"Alcal\u00e1 L, Reigadas E, Mar\u00edn M, Mart\u00edn A, Catal\u00e1n P, Bouza E. Impact of clinical awareness and diagnostic tests on the underdiagnosis of Clostridium difficile infection. Eur J Clin Microbiol Infect Dis. 2015;34(8):1515\u201325.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"813_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1086\/651706","volume":"31","author":"SH Cohen","year":"2010","unstructured":"Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431\u201355.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"12","key":"813_CR5","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1111\/j.1469-0691.2009.03099.x","volume":"15","author":"MP Bauer","year":"2009","unstructured":"Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15(12):1067\u201379.","journal-title":"Clin Microbiol Infect"},{"issue":"S2","key":"813_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1469-0691.12418","volume":"20","author":"SB Debast","year":"2014","unstructured":"Debast SB, Bauer MP, Kuijper EJ, Allerberger F, Bouza E, Coia JE, et al. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(S2):1\u201326.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"813_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jiac.2017.12.003","volume":"24","author":"E Nagy","year":"2018","unstructured":"Nagy E. What do we know about the diagnostics, treatment and epidemiology of Clostridioides (Clostridium) difficile infection in Europe? J Infect Chemother. 2018;24(3):164\u201370.","journal-title":"J Infect Chemother."},{"issue":"4","key":"813_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jhin.2008.08.012","volume":"70","author":"KW Garey","year":"2008","unstructured":"Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70(4):298\u2013304.","journal-title":"J Hosp Infect"},{"issue":"6","key":"813_CR9","doi-asserted-by":"publisher","first-page":"e98400","DOI":"10.1371\/journal.pone.0098400","volume":"9","author":"CN Abou Chakra","year":"2014","unstructured":"Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS ONE. 2014;9(6):e98400.","journal-title":"PLoS ONE."},{"issue":"04","key":"813_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1017\/ice.2014.88","volume":"36","author":"A Deshpande","year":"2015","unstructured":"Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DDK, Hernandez AV, et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36(04):452\u201360.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"8","key":"813_CR11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40266-015-0289-2","volume":"32","author":"M Mizusawa","year":"2015","unstructured":"Mizusawa M, Doron S, Gorbach S. Clostridium difficile diarrhea in the elderly: current issues and management options. Drugs Aging. 2015;32(8):639\u201347.","journal-title":"Drugs Aging"},{"issue":"8","key":"813_CR12","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1111\/ajt.12798","volume":"14","author":"C Mittal","year":"2014","unstructured":"Mittal C, Hassan S, Arshad S, Jeepalyam S, Bruni S, Miceli M, et al. Clostridium difficile infection in liver transplant recipients: a retrospective study of rates, risk factors and outcomes. Am J Transplant. 2014;14(8):1901\u20137.","journal-title":"Am J Transplant"},{"issue":"4","key":"813_CR13","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.vaccine.2009.10.144","volume":"28","author":"BA Leav","year":"2010","unstructured":"Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2010;28(4):965\u20139.","journal-title":"Vaccine."},{"issue":"12","key":"813_CR14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/1469-0691.12769","volume":"20","author":"MP Bauer","year":"2014","unstructured":"Bauer MP, Nibbering PH, Poxton IR, Kuijper EJ, van Dissel JT. Humoral immune response as predictor of recurrence in Clostridium difficile infection. Clin Microbiol Infect. 2014;20(12):1323\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"813_CR15","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/ciw364","volume":"63","author":"SB Gupta","year":"2016","unstructured":"Gupta SB, Mehta V, Dubberke ER, Zhao X, Dorr MB, Guris D, et al. Antibodies to toxin B are protective against Clostridium difficile infection recurrence. Clin Infect Dis. 2016;63(6):730\u20134.","journal-title":"Clin Infect Dis"},{"issue":"7316","key":"813_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nature09397","volume":"467","author":"SA Kuehne","year":"2010","unstructured":"Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature. 2010;467(7316):711\u20133.","journal-title":"Nature"},{"key":"813_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4321\/S1135-57272013000100004","volume":"1","author":"\u00c1 Asensio","year":"2013","unstructured":"Asensio \u00c1, Bouza E, Grau S, Rubio-rodr\u00edguez D, Rubio- C, Rubio-terr\u00e9s C. Cost of Clostridium difficile associated diarrhea in Spain. Rev Esp Salud Publ. 2013;1:25\u201333.","journal-title":"Rev Esp Salud Publ"},{"key":"813_CR18","unstructured":"European Medicines Agency (EMA). Summary of product characteristics. Zinplava (bezlotoxumab). 2017."},{"issue":"4","key":"813_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa1602615","volume":"376","author":"MH Wilcox","year":"2017","unstructured":"Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305\u201317.","journal-title":"N Engl J Med"},{"key":"813_CR20","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos. Bot Plus Web [Internet]. https:\/\/botplusweb.portalfarma.com\/. Accessed 6 Oct 2017."},{"issue":"11","key":"813_CR21","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s40273-017-0540-2","volume":"35","author":"HE Burton","year":"2017","unstructured":"Burton HE, Mitchell SA, Watt M. A systematic literature review of economic evaluations of antibiotic treatments for Clostridium difficile infection. Pharmacoeconomics. 2017;35(11):1123\u201340.","journal-title":"Pharmacoeconomics."},{"issue":"3","key":"813_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/cid\/cix809","volume":"66","author":"VS Prabhu","year":"2018","unstructured":"Prabhu VS, Dubberke ER, Dorr MB, Elbasha E, Cossrow N, Jiang Y, et al. Cost-effectiveness of bezlotoxumab compared with placebo for the prevention of recurrent Clostridium difficile infection. Clin Infect Dis. 2018;66(3):355\u201362.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"813_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10198-010-0244-4","volume":"11","author":"J L\u00f3pez-Bastida","year":"2010","unstructured":"L\u00f3pez-Bastida J, Oliva J, Anto\u00f1anzas F, Garc\u00eda-Alt\u00e9s A, Gisbert R, Mar J, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Heal Econ. 2010;11(5):513\u201320.","journal-title":"Eur J Heal Econ."},{"key":"813_CR24","unstructured":"Clinical study reports of MODIFY I and II trials. Data on file. MSD."},{"key":"813_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/1469-0691.12046","volume":"18","author":"CP Kelly","year":"2012","unstructured":"Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18:21\u20137.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"813_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10096-015-2549-9","volume":"35","author":"T Larrainzar-Coghen","year":"2016","unstructured":"Larrainzar-Coghen T, Rodriguez-Pardo D, Puig-Asensio M, Rodr\u00edguez V, Ferrer C, Bartolom\u00e9 R, et al. First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis. Eur J Clin Microbiol Infect Dis. 2016;35(3):371\u20138.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"813_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.eimc.2012.12.010","volume":"31","author":"D Rodr\u00edguez-Pardo","year":"2013","unstructured":"Rodr\u00edguez-Pardo D, Mirelis B, Navarro F. Infecciones producidas por Clostridium difficile. Enferm Infecc Microbiol Clin. 2013;31(4):254\u201363.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"2","key":"813_CR28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cmi.2014.08.017","volume":"21","author":"MA Olsen","year":"2015","unstructured":"Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect. 2015;21(2):164\u201370.","journal-title":"Clin Microbiol Infect"},{"key":"813_CR29","unstructured":"Spanish National Statistics Institute. Mortality tables for the population of Spain 1991\u20132013 [Internet]. http:\/\/www.ine.es\/jaxi\/Tabla.htm?path=\/t20\/p319a\/serie\/p01\/l0\/&file=01001.px&L=0. Accessed 16 Oct 2017."},{"key":"813_CR30","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1093\/jac\/dkx174","volume":"72","author":"MH Wilcox","year":"2017","unstructured":"Wilcox MH, Ahir H, Coia JE, Dodgson A, Hopkins S, Llewelyn MJ, et al. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life. J Antimicrob Chemother. 2017;72:2647\u201356.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"813_CR31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1186\/s40064-015-1350-7","volume":"4","author":"C Brown","year":"2015","unstructured":"Brown C, Gibson PR, Hart A, Kaplan GG, Kachroo S, Ding Q, et al. Long-term outcomes of colectomy surgery among patients with ulcerative colitis. Springerplus. 2015;4(1):573.","journal-title":"Springerplus."},{"key":"813_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7596-1","volume-title":"Self-reported population health: an international perspective based on EQ-5D","author":"A Szende","year":"2014","unstructured":"Szende A, Janssen B. Self-reported population health: an international perspective based on EQ-5D. Dordrecht: Springer; 2014."},{"key":"813_CR33","unstructured":"Spanish National Statistics Institute. Consumer price index [Internet]. http:\/\/www.ine.es\/calcula\/calcula.do. Accessed 6 Oct 2017."},{"key":"813_CR34","unstructured":"Ortega Eslava A, Mar\u00edn Gil A, Fraga Fuentes M, L\u00f3pez-Briz E, Puigvent\u00f3s Latorre F. Gu\u00eda de evaluaci\u00f3n econ\u00f3mica e impacto presupuestario en los informes de evaluaci\u00f3n de medicamentos. Gu\u00eda pr\u00e1ctica asociada al programa MADRE v 4.0. SEFH. 2016."},{"key":"813_CR35","first-page":"1","volume-title":"Advances in Experimental Medicine and Biology","author":"Elena Reigadas Ram\u00edrez","year":"2018","unstructured":"Reigadas Ram\u00edrez E, Bouza ES. Economic burden of Clostridium difficile infection in European Countries. In: Updates on Clostridium difficile in Europe. 2018. pp. 1\u201312."},{"issue":"5","key":"813_CR36","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1128\/JCM.03352-12","volume":"51","author":"D Rodr\u00edguez-Pardo","year":"2013","unstructured":"Rodr\u00edguez-Pardo D, Almirante B, Bartolom\u00e9 RM, Pomar V, Mirelis B, Navarro F, et al. Epidemiology of clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. J Clin Microbiol. 2013;51(5):1465\u201373.","journal-title":"Spain. J Clin Microbiol."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0813-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-018-0813-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0813-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:35:22Z","timestamp":1724412922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-018-0813-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,16]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0813-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,16]]},"assertion":[{"value":"14 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}